Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

T. Teachey, David; F. Lacey, Simon; A. Shaw, Pamela; Joseph Melenhorst, J.; L. Maude, Shannon; V. Frey, Noelle; Pequignot, Edward; Gonzalez, Vanessa; Chen, Fang; Finklestein, Jeffrey; M. Barrett, David; L. Weiss, Scott; C. Fitzgerald, Julie; A. Berg, Robert; Aplenc, Richard; Callahan, Colleen; R. Rheingold, Susan; Zheng, Zhaohui; Rose‐John, Stefan; C. White, Jason; Nazimuddin, Farzana; Wertheim, Gerald; L. Levine, Bruce; H. June, Carl; L. Porter, David; A. Grupp, Stephan

doi:10.1158/2159-8290.cd-16-0040

Public

Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia

Published in Cancer Discovery • Apr 13, 2016

Authors:

David T. Teachey

Simon F. Lacey

Pamela A. Shaw

Abstract

UNLABELLED: Chimeric antigen receptor (CAR)-modified T cells with anti-CD19 specificity are a highly effective novel immune therapy for relapsed/refractory acute lymphoblastic leukemia. Cytokine release syndrome (CRS) is the most significant and life-threatening toxicity. To improve understanding of...

Subject

Cytokine release syndrome

Chimeric antigen receptor

Cytokine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!